
LENZ Therapeutics Investor Relations Material
Latest events

Q1 2025
LENZ Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from LENZ Therapeutics Inc
Access all reports
LENZ Therapeutics Inc. is a biopharmaceutical company that specializes in the development and commercialization of innovative ophthalmic therapies aimed at improving vision. The company's primary focus is on treating presbyopia, a common age-related condition that affects near vision. LENZ Therapeutics is currently advancing its lead product candidates, LNZ100 and LNZ101, which are in Phase III clinical trials. These products are aceclidine-based eye drops designed to restore near vision for individuals with presbyopia. The company is headquartered in Del Mar, California, and its shares are listed on the NASDAQ.
Key slides for LENZ Therapeutics Inc


Q4 2024
LENZ Therapeutics Inc


Q4 2024
LENZ Therapeutics Inc
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
LENZ
Country
🇺🇸 United States